10-Q: Alphatec Holdings Q3 Revenue Jumps 30%, Narrows Loss

Alphatec Holdings, Inc. reported a 30% increase in third-quarter revenue and a significant reduction in net loss, driven by strong product adoption and strategic debt refinancing.

Summary

• Revenue from products and services increased by $45.8 million, or 30%, to $196.5 million for the three months ended September 30, 2025, compared to $150.7 million in the same period of 2024.
• For the nine months ended September 30, 2025, revenue grew by $116.5 million, or 27%, to $551.2 million, up from $434.8 million in the prior year.
• Net loss significantly narrowed to $(28.6) million, or $(0.19) per share, for the three months ended September 30, 2025, compared to $(39.6) million, or $(0.28) per share, in the same period of 2024.
• Operating loss improved to $(15.9) million for the three months ended September 30, 2025, from $(33.7) million in the prior year.
• Cash provided by operating activities was $24.5 million for the nine months ended September 30, 2025, a substantial improvement from cash used of $(55.2) million in the prior year.
• The company issued $405.0 million in 0.75% Senior Convertible Notes due 2030 in March 2025, with net proceeds of approximately $392.9 million.
• Approximately $268.4 million of the 2030 Notes proceeds were used to repurchase 80% of the 2026 Convertible Notes.
• Total stockholders' equity shifted from a deficit of $(14.2) million at December 31, 2024, to a positive $11.5 million at September 30, 2025.
• Litigation-related expenses increased by $4.4 million, or 212%, to $6.5 million for the three months ended September 30, 2025, primarily due to ongoing litigation and a settlement in May 2025.
• Interest expense, net, increased by $6.3 million, or 96%, to $(12.9) million for the three months ended September 30, 2025, mainly due to the additional draw on the Braidwell Term Loan and amortization of debt discount for the 2030 Notes.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and a significant improvement in operating and net losses, along with a positive shift in operating cash flow. However, increased interest expenses and substantial litigation costs temper the overall positive sentiment.

Positives

• Revenue from products and services increased by 30% for the three months and 27% for the nine months ended September 30, 2025, driven by increased surgeon user base, new product portfolio expansion, and technology adoption.
• Operating loss significantly improved to $(15.9) million for the three months and $(73.3) million for the nine months ended September 30, 2025, compared to larger losses in the prior year periods.
• Net loss narrowed to $(28.6) million for the three months and $(121.6) million for the nine months ended September 30, 2025, representing an improvement of $11.0 million and $7.2 million, respectively, year-over-year.
• Operating activities generated $24.5 million in cash for the nine months ended September 30, 2025, a substantial positive swing from using $(55.2) million in the prior year.
• Stockholders' equity moved from a deficit of $(14.2) million at December 31, 2024, to a positive $11.5 million at September 30, 2025.
• Restructuring expenses decreased by 100% for the three months and 80% for the nine months ended September 30, 2025, due to non-recurring costs from prior period facility relocation and personnel expenses.

Negatives

• Interest expense, net, increased by 96% to $(12.9) million for the three months and 86% to $(33.0) million for the nine months ended September 30, 2025, primarily due to additional debt and amortization of debt discount.
• Litigation-related expenses surged by 212% to $6.5 million for the three months and 136% to $20.3 million for the nine months ended September 30, 2025, due to ongoing litigation and a settlement.
• A loss on debt extinguishment of $(17.6) million was recognized during the nine months ended September 30, 2025, related to the repurchase of 80% of the 2026 Notes.

Risks

• Tariffs and other trade measures could adversely affect business, results of operations, financial position, and cash flows, particularly with increasing international sales and reliance on imported materials.
• Litigation is inherently unpredictable, and an unfavorable resolution in current or future legal proceedings could materially affect future consolidated results of operations, cash flows, or financial position.
• Future capital requirements will depend on factors such as revenue growth rate, spending on development, expansion of sales and marketing, new product introductions, and international business expansion, potentially requiring access to additional funding.
• Exposure to foreign currency exchange risk related to foreign operations may increase as business in markets outside the U.S. continues to grow.

Future Outlook

The company aims to revolutionize the approach to spine surgery through clinical distinction and its InformatiX product platform. It intends to continue adding clinically astute and exclusive sales team members to expand its surgeon user base, penetrate existing accounts, and achieve consistent, predictable growth. Management will continue to monitor current spending levels and cash use, as well as the ability to secure additional credit facilities or term loans to meet future capital requirements.

Management Comments

• "By applying our unique, 100% spine focus and deep, collective industry know-how, we aim to revolutionize the approach to spine surgery through clinical distinction."
• "That adoption-driven validation has been the source of industry-leading market share expansion, which has delivered an approximately 40% revenue compound annual growth rate since our transformation commenced in 2018."

Industry Context

Alphatec Holdings operates in the competitive medical technology sector, specifically focusing on spinal disorders. Its strategy emphasizes a '100% spine focus' and the integration of technology through its 'InformatiX product platform' to differentiate itself. The reported 'industry-leading market share expansion' and 'approximately 40% revenue compound annual growth rate since 2018' suggest that the company is outperforming many industry peers by successfully driving adoption of its specialized procedural approaches and technologies.

Comparison to Industry Standards

• The company reports 'industry-leading market share expansion' and an 'approximately 40% revenue compound annual growth rate since our transformation commenced in 2018', indicating strong performance relative to the broader spine surgery market. No specific comparable companies or projects are detailed in the filing.

Corporate Governance

Legal Proceedings

• In May 2025, the company entered into a settlement with a shareholder to resolve a legal dispute, which contributed to increased litigation-related expenses.
• Ongoing litigation matters also contributed to the increase in litigation-related expenses for the three and nine months ended September 30, 2025.
• The company is a defendant in a lawsuit filed by NuVasive, Inc. against its Chairman and CEO, Mr. Miles, with the Delaware Court ordering NuVasive to advance legal fees for Mr. Miles' defense.

Related Party Transactions

• The company purchased inventory from Squadron Supplier Affiliate, an affiliate of Squadron Capital, LLC, whose President and Director, David Pelizzon, serves on the Company's Board of Directors.
• Inventory purchases from Squadron Supplier Affiliate amounted to $3.1 million for the three months ended September 30, 2025, and $8.2 million for the nine months ended September 30, 2025.
• As of September 30, 2025, the company had $2.9 million due to the Squadron Supplier Affiliate for inventory purchases.

Stakeholder Impact

• Shareholders: Benefit from strong revenue growth, reduced net loss, positive operating cash flow, and the shift from a stockholders' deficit to equity. The 2030 Capped Call Transactions are expected to reduce potential dilution upon conversion of the 2030 Notes.
• Employees: Executive officers participated in a salary-to-equity conversion program, aligning their interests with company performance through RSU grants. Stock-based compensation remains a significant component of overall compensation.
• Customers: Continued expansion of the new product portfolio and technology adoption indicates ongoing innovation and improved surgical solutions for spinal disorders.
• Creditors: The company successfully refinanced a significant portion of its 2026 Notes with longer-term 2030 Notes, and is in compliance with all required financial covenants for its Braidwell Term Loan and Revolving Credit Facility, indicating financial stability.
• Suppliers: The company has an inventory purchase commitment agreement with a third-party supplier, with $6.2 million remaining through December 2026.

Next Steps

• Continue to add clinically astute and exclusive sales team members to reach untapped surgeons, hospitals, and national accounts.
• Better penetrate existing accounts and territories to drive consistent, predictable growth.
• Monitor current level of spending and cash use.
• Monitor the ability to secure additional credit facilities, term loans, or other similar arrangements in light of spending levels and general financial market conditions.

Key Dates

Recommendation

The company demonstrates robust top-line growth with a 30% increase in Q3 revenue and a 27% increase year-to-date, driven by strong product adoption and market share expansion. The significant improvement in operating loss and the shift to positive operating cash flow indicate improving operational efficiency and financial health. While interest expenses have risen due to new debt, the strategic refinancing of the 2026 Notes with longer-term 2030 Notes provides greater financial flexibility. The reduction in net loss and the move from a stockholders' deficit to equity are positive indicators. Despite increased litigation costs, the underlying business momentum and strategic initiatives suggest a strong growth trajectory, making it an attractive investment.

Keywords

Alphatec Holdings, ATEC, Spine Surgery, Medical Technology, SEC Filing, 10-Q, Financial Results, Convertible Notes, Debt Refinancing, Spinal Implants, EOS Imaging, Surgical Instruments, Revenue Growth, Net Loss, Cash Flow, Corporate Governance